Results 161 to 170 of about 137,923 (290)

Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in patients with non-Hodgkin's lymphoma in the United Kingdom (UK) [PDF]

Introduction: We report a cost-effectiveness evaluation of granulocyte colony-stimulating factors (G-CSFs) for prevention of febrile neutropenia (FN) following chemotherapy for non-Hodgkin’s lymphoma (NHL) in the United Kingdom (UK).
Akehurst, R., Cooper, K.L., Stevenson, M.D., Whyte, S.   +3 more
core  

Semen Quality in Patients with Hematological Malignancies: A Retrospective Monocentric Study in the Perspective of Personalized Oncofertility Medicine. [PDF]

J Pers Med
Cariati F, Orsi MG, Capasso A, Pagano D, Bagnulo F, Iorio GG, Trinchillo MG, Ordichelli R, Guido M, Estrusco A, Alviggi C, Conforti A.   +11 more
europepmc   +1 more source

Prognostic role of PET/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL Group

British Journal of Haematology, EarlyView.
A visual overview of the key findings from the 35 papers included in this systematic review evaluating the use of PET volumetric parameters in children, adolescents and young adults with Hodgkin lymphoma. Summary In adults with classic Hodgkin lymphoma (cHL), metabolic tumour volume (MTV) is valuable for risk stratification.
S. Claire Gowdy, Jamie E. Flerlage, Jennifer Seelisch, Monica Palese, Tyler Bradshaw, Sharon M. Castellino, Steve Cho, Karin Dieckmann, Bradford S. Hoppe, Scott Howard, Kara M. Kelly, Lars Kurch, Hollie A. Lai, Egesta Lopci, John T. Lucas Jr., Christine Mauz‐Körholz, Kathleen M. McCarten, Neeta Pandit‐Taskar, Heiko Schöder, Jonas Steglich, Dietrich Stoevesandt, Stephan D. Voss, Sarah A. Milgrom   +22 more
wiley   +1 more source

Long-term survival and successful pregnancy in a Nigerian woman with concurrent diagnosis of non-Hodgkin lymphoma and chronic myeloid leukemia: a case report. [PDF]

J Med Case Rep
Ahmed IO, Ogunrinde VO, Asafa MA, Agim MB, Adeleke AA, Ayodele SO, Adesunkanmi OO, Ogunoye BT, Adegbenro ST, Bolarinwa RA, Salawu L, Durosinmi MA.   +11 more
europepmc   +1 more source

Medical haematology: Repositioning haematology at the centre of medicine

British Journal of Haematology, EarlyView.
The complementary domains of Medical Haematology and Haemato‐Oncology share a biological framework. The left panel depicts red cells, platelets, coagulation, thrombosis and innate immunity, while the right panel shows lymphoid and myeloid malignancies.
Cheng Hock Toh, Imelda Bates, Sue Pavord
wiley   +1 more source

Synchronous primary pulmonary extranodal NK/T-cell lymphoma and relapsed Hodgkin lymphoma occurring after chemotherapy for primary Hodgkin lymphoma: A case report and literature review. [PDF]

Rare Tumors
Corredor-Orlandelli D, Bohórquez L, Arévalo-Zambrano M.   +2 more
europepmc   +1 more source

Clonal haematopoiesis in T‐follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution

British Journal of Haematology, EarlyView.
Summary T‐follicular helper cell lymphomas (TFHLs) are frequently associated with epigenetic mutations and clonal haematopoiesis (CH), but the clinical and prognostic implications of CH in TFHL remains unclear. We performed next‐generation sequencing on paired peripheral blood (PB) and tumour tissue samples from 30 patients with TFHL. CH was defined by
Chong Wei, Yan Zhang, Danqing Zhao, Wei Zhang, Daobin Zhou   +4 more
wiley   +1 more source

Anaplastic large-cell lymphoma mimicking cellulitis in an 8-year-old boy. [PDF]

CMAJ
Bourque M, Coulombe J.
europepmc   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

Risk of lymphoma among people with HIV in the United States, 2001-2019. [PDF]

J Natl Cancer Inst
Tao J, Luo Q, Haas CB, Mbulaiteye SM, Hayes J, Cohen C, Pawlish KS, Cherala S, Engels EA, Morton LM, Shiels MS.   +10 more
europepmc   +1 more source